Liver Cancer

Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma

Wayne Kuznar

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Cholangiocarcinoma, Liver Cancer

Chicago, IL—A greater understanding of the biology of cholangiocarcinoma, including differences between intrahepatic versus extrahepatic cholangiocarcinoma, is driving the development of new therapeutic options that have shown promising results in advanced stages of this difficult-to-treat cancer. Patients whose disease progressed [ Read More ]

Lenvatinib Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma: Results from the REFLECT Clinical Trial

Walter Alexander

Liver Cancer

Chicago, IL—Beyond demonstrating noninferiority for overall survival (OS) in advanced, unresectable hepatocellular carcinoma (HCC), lenvatinib (Lenvima) demonstrated superiority over sorafenib (Nexavar) in progression-free survival (PFS), time to progression, and overall response rate in the REFLECT clinical trial, reported lead investigator Ann-Lii Cheng, MD, National Taiwan University Hospital, Taipei, in an oral presentation at the 2017 ASCO annual meeting. With nearly 745,000 deaths attributed to HCC annually, HCC is the second leading cause of death worldwide, noted Dr Cheng. [ Read More ]